Announcements
- Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
- Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
- Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord
- Crossject annonce le vif succès de son augmentation de capital de 8 millions d’euros
- Crossject announces highly successful closing of its €8 million rights offering
- Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
- Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy
- Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en Europe
- Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
- Crossject annonce le lancement d’une augmentation de capital
More ▼
Key statistics
On Friday, Crossject SA (74C:DEU) closed at 1.71, 0.00% above its 52-week low of 1.71, set on Jun 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.74 |
---|---|
High | 1.84 |
Low | 1.71 |
Bid | 1.53 |
Offer | 1.81 |
Previous close | 1.82 |
Average volume | 167.80 |
---|---|
Shares outstanding | 41.09m |
Free float | 31.20m |
P/E (TTM) | -- |
Market cap | 68.21m EUR |
EPS (TTM) | -0.2329 EUR |
Data delayed at least 15 minutes, as of Jun 14 2024.
More ▼